Abstract
No public abstract is available from the verified source records.
Bingwen Eugene Fan, Anuja Premawardhena
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Thalassaemia
10.1016/s0140-6736(22)00536-0 · 2022
The epidemiology of thalassaemia syndromes in southeast Asia
2026
Thalassaemia prevention in Asia: progress, challenges, and future directions
2026
The expanding therapeutic landscape of β-thalassaemia
2026
Future-proofing thalassaemia care: harnessing scalable therapies, artificial intelligence, and global collaboration
2026
Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial
10.1016/s0140-6736(23)00874-7 · 2023
Mitapivat in adults with non-transfusion-dependent α-thalassaemia or β-thalassaemia (ENERGIZE): a phase 3, international, randomised, double-blind, placebo-controlled trial
10.1016/s0140-6736(25)00635-x · 2025
The dawn of the CRISPR/Cas9 gene therapy era
10.1016/s2352-3026(23)00372-1 · 2024
Betibeglogene autotemcel gene therapy in patients with transfusion-dependent, severe genotype β-thalassaemia (HGB-212): a non-randomised, multicentre, single-arm, open-label, single-dose, phase 3 trial
10.1016/s0140-6736(24)01884-1 · 2024
From microscope to micropixels: a rapid review of artificial intelligence for the peripheral blood film
10.1016/j.blre.2023.101144 · 2024
No additional external references are available.